Cocrystal Pharma
COCP
22 hedge funds and large institutions have $5.71M invested in Cocrystal Pharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
22% more funds holding
Funds holding: 18 → 22 (+4)
0.02% more ownership
Funds ownership: 0.72% → 0.74% (+0.02%)
11% less capital invested
Capital invested by funds: $6.41M → $5.71M (-$700K)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
+$105K |
| 2 |
Millennium Management
New York
|
+$28.5K |
| 3 |
SS
Sunbelt Securities
Houston,
Texas
|
+$25.9K |
| 4 |
Renaissance Technologies
New York
|
+$22.7K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$5.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$36K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$9.87K |
| 3 |
BlackRock
New York
|
-$4.15K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| 5 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$1.92K |
COCP Hedge Fund Activity: Q3 2019 in Review
22 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q3 2019, worth a combined $5.71M — down 11% from $6.41M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new COCP positions and 3 closed out — a net gain of 4 holders — while 1 added to existing stakes and 6 trimmed.
The largest buyer was Parallel Advisors, opening a new position worth an estimated $105K. The largest seller was Citadel Advisors, exiting entirely with an estimated $36K sold.
- 22 institutional investors held Cocrystal Pharma (COCP) as of Q3 2019, up from 18 in Q2 2019.
- Funds reported $5.71M of Cocrystal Pharma stock for Q3 2019, down 11% quarter-over-quarter.
- 7 funds opened new Cocrystal Pharma positions in Q3 2019 and 3 closed out, a net change of +4 holders.
- The largest Cocrystal Pharma buyer in Q3 2019 was Parallel Advisors, an estimated $105K added.
- The largest Cocrystal Pharma seller in Q3 2019 was Citadel Advisors, an estimated $36K sold.
Based on aggregated 13F filings for Q3 2019.